ArticleNano today2015
Engineered Materials for Cancer Immunotherapy.
Article in Nano today, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- STING stimulation via supramolecular prodrug hydrogel boosts innate-adaptive immune cross-talk to prevent glioblastoma recurrence.Science advances · 2026Article
- Dendritic Cell-Hitchhiking In Vivo for Vaccine Delivery to Lymph Nodes.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- A novel microporous biomaterial vaccine platform for long-lasting antibody mediated immunity against viral infection.Journal of controlled release : official journal of the Controlled Release Society · 2024Article
- Tertiary lymphoid structural heterogeneity determines tumour immunity and prospects for clinical application.Molecular cancer · 2024Review
- Harnessing 3D in vitro systems to model immune responses to solid tumours: a step towards improving and creating personalized immunotherapies.Nature reviews. Immunology · 2024Review
- Recent advancements in single dose slow-release devices for prophylactic vaccines.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2023Review
- Three-dimensional (3D) scaffolds as powerful weapons for tumor immunotherapy.Bioactive materials · 2022Review
- Nanoparticle-Based Drug Delivery Systems Targeting Tumor Microenvironment for Cancer Immunotherapy Resistance: Current Advances and Applications.Pharmaceutics · 2022Review
- Spatial delivery of immune cues to lymph nodes to define therapeutic outcomes in cancer vaccination.Biomaterials science · 2022Article
- Recent advances in porous nanomaterials-based drug delivery systems for cancer immunotherapy.Journal of nanobiotechnology · 2022Review
- Innovations in Disease State Responsive Soft Materials for Targeting Extracellular Stimuli Associated with Cancer, Cardiovascular Disease, Diabetes, and Beyond.Advanced materials (Deerfield Beach, Fla.) · 2021Review
- Nanoparticles for Enhanced Adoptive T Cell Therapies and Future Perspectives for CNS Tumors.Frontiers in immunology · 2021Review
- Immunostimulatory biomaterials to boost tumor immunogenicity.Biomaterials science · 2020Review
- Advances in engineering local drug delivery systems for cancer immunotherapy.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2020Review
- The functions and applications of A7R in anti-angiogenic therapy, imaging and drug delivery systems.Asian journal of pharmaceutical sciences · 2019Review
- T cell immunotherapy enhanced by designer biomaterials.Biomaterials · 2019Review
- Designing inorganic nanomaterials for vaccines and immunotherapies.Nano today · 2019Article
- Advances in immunotherapy delivery from implantable and injectable biomaterials.Acta biomaterialia · 2019Review
- Targeted Therapy against Metastatic Melanoma Based on Self-Assembled Metal-Phenolic Nanocomplexes Comprised of Green Tea Catechin.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2019Article
- Nanomedicine and macroscale materials in immuno-oncology.Chemical Society reviews · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Immunotherapy is a promising treatment modality for cancer as it can promote specific and durable anti-cancer responses. However, limitations to current approaches remain. Therapeutics administered as soluble injections often require high doses and frequent re-dosing, which can result in systemic toxicities. Soluble bolus-based vaccine formulations typically elicit weak cellular immune responses, limiting their use for cancer. Current methods for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.